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Background: Neuromyelitis optica (NMO, Devic syndrome) is associated with antibodies to aquaporin-4 (NMO-IgG/
AQP4-Ab) in the majority of cases. NMO-IgG/AQP4-Ab seropositivity in patients with NMO and its spectrum
disorders has important differential diagnostic, prognostic and therapeutic implications. So-called cell-based assays
(CBA) are thought to provide the best AQP4-Ab detection rates.
Objective: To compare directly the AQP4-IgG detection rates of the currently most widely used commercial CBA,
which employs cells transfected with a full-length (M1)-human AQP4 DNA in a fashion that allows leaky scanning
(LS) and thus expression of M23-AQP4 in addition to M1-AQP, to that of a newly developed CBA from the same
manufacturer employing cells transfected with human M23-AQP4-DNA.
Methods: Results from 368 serum samples that had been referred for routine AQP4-IgG determination and had
been tested in parallel in the two assays were compared.
Results: Seventy-seven out of 368 samples (20.9%) were positive for NMO-IgG/AQP4-Ab in at least one assay. Of
these, 73 (94.8%) were positive in both assays. A single sample (1.3%) was exclusively positive in the novel assay;
three samples (3.9%) were unequivocally positive only in the ‘classic’ assay due to high background intensity in the
novel assay. Both median fluorescence intensity and background intensity were higher in the new assay.
Conclusions: This large study did not reveal significant differences in AQP4-IgG detection rates between the ‘classic’
CBA and a new M23-DNA-based CBA. Importantly, our results largely re-affirm the validity of previous studies that
had used the ‘classic’ AQP4-CBA to establish NMO-IgG/AQP4-Ab seropositivity rates in NMO and in a variety of
NMO spectrum disorders.
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Neuromyelitis optica (NMO) is an often severely disabling
syndrome characterized by optic neuritis (ON) and myeli-
tis [1-4]. In 2004, Lennon and colleagues described a novel
IgG serum reactivity present in around 60 to 80% of pa-
tients with NMO (termed NMO-IgG) [5,6], which was
subsequently shown to target aquaporin-4 (AQP4), the
most abundant water channel in the central nervous sys-
tem (CNS) [7,8]. In the meantime, AQP4-IgG have been
demonstrated to be directly pathogenic and of high differ-
ential diagnostic and prognostic impact [9-13], classifying
seropositive NMO as part of an expanding spectrum of
humorally mediated autoimmune syndromes of the CNS
[14-21]. AQP4-IgG were also demonstrated to confer a
high risk of conversion into NMO in patients presenting
with a first attack of myelitis or ON [1,22-24]. Moreover,
some studies suggested that AQP4-IgG seropositivity
might be associated with a more severe disease course in
patients with NMO [1,25]. Most importantly, however, the
presence of AQP4-IgG permits differentiation between
NMO and multiple sclerosis - two conditions that can
be difficult to distinguish on clinical grounds and the
optimum treatments of which differ - by means of a la-
boratory test [26-31].
Over the past couple of years, several immunoassays
for the detection of AQP4-IgG have been developed,
which vary significantly with regard to sensitivity, speci-
ficity and reproducibility (see [28] for a comprehensive
overview). Currently, so-called cell-based assays (CBAs),
most of which employ HEK293 cells transfected with
human AQP4, are considered to provide the best com-
promise between assay performance and practical feasi-
bility. CBAs have been shown to be both more sensitive
and more specific than immunohistochemistry, the previ-
ous gold standard, enzyme-linked immunosorbent assays
and some immunofluorescence assays [26-30,32,33].
At least two isoforms of human AQP4 exist. Recently,
it has been suggested that the shorter M23 isoform
might be preferential with regard to assay sensitivity. It
has been argued that AQP4-IgG might partly target epi-
topes formed upon the formation of M23-AQP4 to so-
called orthogonal arrays of particles (OAPs) [34]. In fact, a
recent study has demonstrated higher AQP4-IgG binding
affinity to M23-AQP4 than M1-AQP4 [35].
The currently most widely used commercial CBA em-
ploys cells transfected with so-called M1-AQP4-DNA. In
four previous studies on European and North American
patients and control subjects by three independent groups,
this assay yielded median sensitivity of 78.6% (N = 103)
and specificity of 100% (N = 322), corresponding to a
positive likelihood ratio of ∞ and a negative likelihood
ratio of 0.21 (CI 95% 0.14 to 0.3) [26,32,36,37]. From
both a clinical and a scientific point of view, it would be
important to know whether the data on AQP4-IgGfrequencies obtained using that assay in the past are
valid or if they represent an underestimate caused by
the use of M1- instead of M23-AQP4-DNA. Of note,
however, the sequence of the construct used by the
manufacturer in that ‘classic’ assay contains a C at pos-
ition -3, which has recently been shown by Pisani et al.
to result in strong co-expression of M23 due to leaky
scanning (LS); this might well compensate for the use of
M1 DNA [38,39]. In the present study we directly com-
pared the detection rates of the ‘classic’ M1-DNA-based
CBA with LS and of an M23-DNA-based CBA newly
developed by the same manufacturer. To this end, we
evaluated results from 368 sera tested in parallel in the
two CBAs.Patients and methods
Slides with five wells each containing biochips coated
with formalin-fixed M1-AQP4-transfected HEK293 cells
(sense primer ATACGTCTCAAGCTTATGAGTGACA
GACCCACAGCAAGGCGGTG and reverse primer AT
ACGTCTCCTCGAGTCATACTGAAGACAATACCTC
TCCAGATTGGTC; [26]), M23-AQP4-transfected HEK293
cells (sense primer ATAAGGTCTCCCATGGTGGCTTT
CAAAGGGGTCTGGAC and reverse primer ATACGTC
TCCTCGAGTCATACTGAAGACAATACCTCTCCAGA
TTGGTC) and mock-transfected HEK293 cells were ob-
tained from Euroimmun (Luebeck, Germany). Correctness
of the AQP4-encoding DNA was verified by sequencing
by the manufacturer. For standardization of the immuno-
logical analyses, the TITERPLANE™ technique was used
according to the manufacturer’s instructions as described
[26]. In short, samples (at standard 1:10 dilution in 1%
BSA in PBS) or labeled antibodies were applied to the re-
action fields of a reagent tray. The biochip slides were then
placed into the recesses of the reagent tray, where all bio-
chips of each slide came into contact with the fluids, and
the individual reactions commenced simultaneously. After
incubation for 60 min at room temperature, the slides
were rinsed with a flush of PBS-Tween and incubated in
PBS-Tween for at least 5 min. Bound IgG were labeled
using fluorescein-conjugated goat anti-human IgG anti-
body for 60 min and washed as described before. All sera
were analyzed by the same assessor (10 years’ experience
in indirect immunofluorescence assaying and 5 years’ ex-
perience with the M1-AQP4 CBA used here), who was
unaware of patients’ diagnoses. Typical findings are shown
in the Figure 1. Sera were classified as positive in assay A
(M1-DNA-based CBA with LS), positive in assay B (M23-
DNA-based CBA), or positive in both assays as previously
described [26]. In addition, all positive samples were semi-
quantitatively scored based on the intensity of the surface
staining using a five-point scale (1: very weak staining,
may require 20x magnification for affirmation; 2: weak; 3:
Figure 1 Neuromyelitis optica (NMO)-IgG/AQP4-Ab as detected by an M23-DNA-AQP4-based, cell-based assay (CBA) and an
M1-AQP4-DNA-based CBA with leaky scanning (LS). M23-AQP4-DNA-transfected cells (A), M1- AQP4-DNA-transfected cells with LS (B) and
mock-transfected cells (C) were incubated in the same well on separate biochips. Note the higher signal intensity observed in the M23-AQP4-
DNA-based assay in a direct comparison with the M1-AQP4-DNA-based assay observed with this particular sample (NMO#1). Panel D and E
show results obtained with serum from a healthy control donor. Photographs were taken with a Nikon Ni-E upright, wide-field, research
microscope using identical exposure times and camera settings. Binding of NMO-IgG/AQP4-Ab was visualized using a FITC-labeled anti-human
IgG antibody. FITC = fluorescein isothiocyanate; HC = healthy control.
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fluorescence may overshine parts of the cytoplasm).
AQP4-IgG test results in 368 unselected serum sam-
ples from 341 subjects (median age 44 years, range 1 to
92) that had previously been referred and tested in paral-
lel in the two assays for clinical routine purposes were
retrospectively analyzed in a strictly anonymized fashion
as part of an internal quality audit, i.e. without access to
patient names or other identifiers. No samples were
taken for the purpose of this study. Statistical analysis
was performed using Microsoft Excel and GraphPad Prism.
In addition, two samples that had previously yielded a
negative result in another, independent C−3-M1-AQP4-
DNA-based assay [40] but a positive result in its M23-
DNA-based counterpart were retrospectively tested in the
two assays; testing was approved by the institutional re-
view board of the University of Heidelberg and patients
gave informed written consent.
Results
Seventy-seven out of 368 samples (20.9%) were positive
for AQP4-IgG in one of the two assays. Testing in assay B
resulted in stronger surface immunofluorescence intensityscores than in assay A in a direct comparison of biochips
within the same well in the majority of cases (see the
Figure 1 for an example). Seventy-three out of 77 samples
(94.8%) were positive in both assays; only one sample
(1.3%) was positive exclusively in assay B (fluorescence in-
tensity score 1; diagnosis indicated by the referring center:
‘NMO according to Wingerchuk’s 2006 criteria’); three
samples (3.9%) were exclusively positive in assay A (fluor-
escence intensity scores: one in two cases, two in one case;
1 × ‘NMO according to Wingerchuk’s 2006 criteria’, one ×
‘myelitis and ON’, but no clinical information provided by
the referring center on whether Wingerchuk’s 2006 cri-
teria were met, and one × ‘myelitis’) due to higher back-
ground fluorescence observed in the M23-DNA-based
cells, which prevented unequivocal distinction between
AQP4-specific and non-specific fluorescence in these par-
ticular cases; 291 samples were negative both in assay A
and in assay B (Table 1). Seropositivity rates did not differ
significantly between assay A (20.7%) and assay B (20.1%)
(P = n.s., Fisher exact test). Cohen kappa, as a measure of
interassay reliability, was 0.967 (CI 95% 0.934 to 0.999).
Thirty-eight samples yielded higher signal intensity scores
in assay B; no significant difference in signal intensity was
Table 1 Neuromyelitis optica (NMO)-IgG/AQP4-Ab
seropositivity rates as found in an M1-AQP4-DNA-based
cell-based assay with leaky scanning (LS, ‘assay A’) and in
an M23-AQP4-DNA-based cell-based assay (’assay B’)
NMO-IgG/AQP4-Aba
Positive
Either assay A or B 77/368 (20.9%)
Assay A 76/368 (20.7%)
Assay B 74/368 (20.1%)
Both assay A and B 73/77 (94.8%)
Assay A only 3/77 (3.9%)
Assay B only 1/77 (1.3%)
Negative
Neither assay A nor B 291/368 (79.1%)
aM1-DNA- and M23-DNA-transfected cells were tested simultaneously on separate
biochips within the same well to ensure identical incubation conditions.
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assay A. Median signal intensity among AQP4-IgG-
positive samples was 4 (range, 1 to 5) in assay B compared
to 3.5 (range 1 to 5) in the assay A at a 1:10 dilution
(P <0.002; Mann-Whitney U test). The median differ-
ence in signal intensity score was 1 (range 1 to 3); with
a difference of 1 in 40 cases, of 2 in 9 cases, and of 3
in 1 case. Very weak or weak staining (fluorescence inten-
sity (FI) scores 1 or 2) was observed with 14 AQP4-IgG-
positive samples using assay A but with only 7 using assay
B; in contrast, maximum signal intensity (FI score 5) was
noted with 20 AQP4-IgG-positive samples using assay, B
but only with 6 AQP4-IgG-positive samples using the
assay A (P <0.005; Chi square test; n = 77). The two sam-
ples that had previously yielded a positive result in an in-
dependent M23-DNA-based CBA but a negative result in
its C−3-M1-DNA-based counterpart [40] and were tested
in addition yielded a positive result in both assays (sample
1: FI score 3 in assay A, FI score 4 in assay B; sample 2: FI
score 4 in assay A, FI score 5 in assay B).Discussion
In the present study, one of the largest on NMO-IgG/
AQP4-IgG testing so far (n = 368), we found no significant
difference in positivity rates between the currently most
widely used commercial CBA, which employs HEK293
cells transfected with a construct based on C−3-M1-
AQP4-DNA allowing for LS, and a newly developed
M23-DNA-based CBA from the same manufacturer,
despite higher median signal intensity in the new assay.
Importantly, M1- and M23-AQP4-transfected cells were
incubated in the same well and thus analyzed simultan-
eously under identical conditions. Most notably, only a
single sample was positive exclusively in the novel M23-
AQP4-DNA-based assay.This is clinically important given that (a) the M1-
DNA-based (‘classic’) assay evaluated here has been used
by many laboratories over the past couple of years and
employed in many scientific studies on NMO and its
spectrum disorders, and (b) some recent studies have
suggested that transfection with the shorter, so-called
M23 isoform of AQP4 might improve assay sensitivity.
That latter assumption is corroborated by preliminary
evidence suggesting that AQP4-Ab may partly bind to
conformational epitopes linked to OAP formation or
that larger OAPs could enhance NMO-IgG/AQP4-Ab
binding [34,35,40,41].
There are at least two possible explanations between
the hypothesis that transfection with M23-AQP4 is pref-
erential in terms of sensitivity [34] and the finding of
almost equal sensitivity in practice as observed in the
present and in previous studies. First, NMO patients
may simply harbor not only M23-specific AQP4-IgG in
their serum but generally also an amount of AQP4-IgG
binding to M1-AQP4, or both M1-AQP4 and M23-AQP4,
sufficient to yield positive test results also in M1-based
assays. In fact, recent affinity studies using AQP4-
transfected human astrocyte-derived U87MG cells found
binding to both isoforms, though consistently stronger
binding to M23 with wide variations in NMO-IgG/
AQP4-Ab binding intensity to M1- versus M23-AQP4
among patients and even among recombinant monoclo-
nal AQP4-Abs generated from different plasma cell
clones of a single patient [35]. Second, and importantly,
Pisani et al. recently demonstrated that LS-induced by a
C or T in position N−3 may result in substantial expres-
sion of M23-AQP4 in HEK293 cells even if M1-AQP4-
DNA is employed [38,39]. Given that the sequence
employed in the M1-AQP4-DNA-based CBA used in
our study in fact contains a C at position N−3, expres-
sion of M23 due to LS is indeed a likely explanation for
our finding of equal AQP4-IgG detection rates of the
two assays. Future studies employing full-length AQP4-
DNA should pay special attention to vector preparation
and possible LS.
However, other factors may also play a role, as indi-
cated by the fact that samples from our laboratory that
had been found negative in another C−3-M1-AQP4-
DNA-based CBA, but positive in its M23-DNA-based
counterpart [40], were unequivocally positive in both of
the two assays evaluated in the present study. Such factors
may include differences in secondary antibodies, pre-
analytical sample treatment (pre-adsorption with rabbit
liver powder as used in reference [40] versus no pre-
adsorption in the present study), starting dilutions, use of
tagged versus untagged AQP4, differences in expression
levels etc.
In line with our findings, many assays employing M1-
AQP4-DNA in the past have yielded high sensitivity rates
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no difference between M1 and M23 assays [28]. A recent
ELISA study reported similar positivity rates between de-
natured M23-AQP4 and denatured M1-AQP4 though the
average OD value was approximately 20% higher with
AQP4-M23 [31]. Similarly, no increase in sensitivity rates
was found on direct comparison between an M1-AQP4-
based and an M1 +M23-AQP4-based fluorescence-based
immunoprecipitation assay [32] as well as in a FACS study
[42]. Finally, a recent study found no substantial M23 ex-
pression in M1-transfected HEK293 cells [43] and two
studies suggested binding of AQP4-IgG-positive samples
to both M1 and M23 tetramers, as well as to M1, in the
absence of high-order arrays [43,44]. Unfortunately, the
exact vector sequences used in some of those studies were
not reported, which makes it impossible to decide whether
LS played a role or not.
However, investigations of the molecular mechanisms
underlying the differential performance of the various
assays available were not the objective of the present
study, which focuses on the practical, that is, clinical,
value of the two assays evaluated here.
Although we found only a single sample in the present
cohort that was positive for AQP4-Ab only in the M23-
DNA-based assay, the generally higher signal intensity
observed with that substrate resulted in a lower number
of samples classified as very weakly positive. Such sam-
ples can well pose a challenge to less specialized asses-
sors in routine laboratories, and higher signal intensity
would facilitate diagnosis in those cases. If it would be
possible to improve the signal-to-noise ratio of the M23-
based assay evaluated here without reducing sensitivity,
that assay could be an important step forward.
In the present study, formalin-fixed cells were used. A
previous study suggested that use of live cells might fur-
ther improve AQP4-IgG detection rates [32]. However,
the lack of a sufficiently large control cohort in that
study makes it difficult to appreciate fully the specificity
of the respective live-cell assay and, thus, to decide
whether all of the reported additional positives were true
positives. Of note, the previous C−3-M1-AQP4-DNA-
based CBA [40] that had yielded a negative result in two
samples clearly positive in the present fixed-cell C−3-
M1-AQP4-DNA-based CBA (and in two independent
M23-DNA-based assays) had been a live-cell assay, indi-
cating that other factors may compensate for the use of
fixed cells. Moreover, live-cell assays have a number of
potential disadvantages: First, live-cell assays are not
exactly standardizable because cells have to be newly
transfected before each run and transfection rates may
thus vary over time; this potentially prevents their usability
for long-term monitoring. Stably transfected cells might
be advantageous in this regard; however, expression rates
may still drop to some extent and thus need to bemonitored over time. Second, live-cell assays require cell
culture facilities and highly specialized personal and are
thus available only at very few specialized laboratories
worldwide. Third, compared to commercially available,
ready-to-use fixed cell assays, live-cell assays are usually
more time- and labor-consuming and thus less suitable
for routine laboratories not focusing on AQP4-IgG testing.
While live-cell assays may prove useful in the context of
scientific studies, standardized assays that can be made
readily available to all laboratories providing routine test-
ing for autoantibodies are important for everyday clinical
practice.
In summary, the present study argues against an urgent
need to substitute the currently widely used C−3-M1-
AQP4-DNA-based CBA with LS first described by us in
2010 with an M23-AQP4-DNA-based CBA and, import-
antly, largely affirms the validity of the numerous studies
that used that assay for assessing the frequency of NMO-
IgG/AQP4-IgG seropositivity in NMO spectrum disorders
(for example, [12,22,26,27,45-50]). While this particular
M1-DNA-based assay showed similar positivity rates to an
M23-DNA-based assay, it should be underlined that this
does not imply general equivalence between M1- and
M23-DNA-based assays. LS and other factors specific to
this particular assay may have played an important role.
This should be considered when it comes to developing
future assays for detecting AQP4-IgG based on full-length
AQP4-DNA. The higher signal intensity observed in the
M23 cells could be especially advantageous when it comes
to detecting low AQP4-IgG titers in patients under im-
munosuppressive treatment and might thus facilitate
long-term monitoring of AQP4-IgG titers in such patients.
Finally, the worse signal-to-noise ratio observed with some
samples in the M23 assay, the cause of which is unknown,
might limit the diagnostic value of the M23-based CBA
evaluated here and warrants further endeavors to optimize
that assay.
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